New Parkinson's drug enters early human testing
NCT ID NCT06565195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called LY3962681 in healthy volunteers and people with Parkinson's disease. The goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo injected into the spinal fluid, and are followed for up to a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Clinic PPD
RECRUITINGAustin, Texas, 78744-1625, United States
-
Ehime University Hospital
NOT_YET_RECRUITINGTōon, Ehime, 791-0295, Japan
-
Oita University Hospital
NOT_YET_RECRUITINGYufu, Oita Prefecture, 879-5593, Japan
-
P-One Clinic, Keikokai Medical Corporation
RECRUITINGHachiōji, Tokyo, 192-0071, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Can brain stimulation sharpen Decision-Making in Parkinson's?
- Can Stem-Cell implants restore movement in Parkinson's?
- Wild blueberries put to the test for Parkinson's motor symptoms
- Could tailored brain stimulation quiet Parkinson's tremors more effectively?
- Zapping away tremors: scientists probe how electrical stimulation calms shaky hands